OncoMatch/Clinical Trials/NCT06712121
Venetoclax and Decitabine in R/R T-ALL
Is NCT06712121 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies decitabine plus venetoclax for t lymphoblastic leukemia/lymphoma.
Treatment: decitabine plus venetoclax — The goal of this phase 2 clinical trial is to test the efficacy of decitabine and venetoclax combination chemotherapy in relapsed or refractory adult T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. This study use a modified regimen of decitabine and venetoclax.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: induction chemotherapy
relapse or failure to achieve complete remission despite induction chemotherapy
Cannot have received: venetoclax + decitabine (venetoclax, decitabine)
Exception: participants who received venetoclax + decitabine treatment for a different type of cancer (e.g., acute myeloid leukemia) and have elapsed more than 1 year since the last treatment are allowed
Individuals who previously received venetoclax + decitabine treatment for T-lymphoblastic leukemia/lymphoma
Lab requirements
Blood counts
peripheral blood leukocytes <50,000/uL (reducing white blood cell count through hydroxyurea or leukapheresis prior to trial enrollment is allowed)
Kidney function
calculated GFR ≥ 30 mL/min according to Cockcroft-Gault formulas, or creatinine ≤ 1.4
Liver function
total bilirubin ≤ 3.0 mg/dL, AST and ALT < x5 upper limit of normal (ULN); if bilirubin elevation is due to Gilbert's syndrome or liver enzyme elevation is due to infiltration of leukemia/lymphoma, enrollment may be allowed even if the above conditions are exceeded
peripheral blood leukocytes <50,000/uL (reducing white blood cell count through hydroxyurea or leukapheresis prior to trial enrollment is allowed); calculated GFR ≥ 30 mL/min according to the Cockcroft-Gault formulas, or creatinine ≤ 1.4, total bilirubin ≤ 3.0 mg/dL, and AST and ALT < x5 upper limit of normal (ULN) (however, if bilirubin elevation is due to Gilbert's syndrome or liver enzyme elevation is due to infiltration of leukemia/lymphoma, enrollment may be allowed even if the above conditions are exceeded)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify